Literature DB >> 28872088

[Clinical characteristics and prognosis for 126 patients with severe drug eruption].

Jie Li1, Manyun Mao1, Ni Tang1, Rui Zhai1, Wu Zhu1, Mei Yi1, Mingliang Chen1.   

Abstract

OBJECTIVE: To explore the clinical characteristics of various types of severe drug eruption and common sensitized drugs, and to provide clinical references for reducing the incidence of severe drug eruption.

Methods: The clinical data regarding 126 cases of severe drug eruption were analyzed retrospectively from June 2009 to May 2017 in Xiangya Hospital, Central South University.

Results: In the 126 cases of severe drug eruption, the distribution of men and women ratio was 1:1.38. The length of stay was (12.7±9.8) d. The most common type was Steven-Johnson syndrome; the most dangerous type was drug-induced bullosa epidermolysis. The most common sensitized drug category in these patients was antibiotics; the most common single sensitizing drug was carbamazepine, following by allopurinol.

Conclusion: Severe drug eruption occurs mostly in young and middle-aged people. Steven-Johnson syndrome is the most common type; drug hypersensitive syndrome has the longest length of hospital course. Mortality rate of drug-induced bullosa epidermolysis is the highest. Timely stop using of allergens, early using glucocorticoids, and timely combination of non-glucocorticoids treatment (such as intravenous immunogloblin, plasma exchange and hemodialysis), can improve the efficacy and reduce the complications and mortality. 
.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28872088     DOI: 10.11817/j.issn.1672-7347.2017.08.013

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  1 in total

1.  Autologous scalp skin grafting to treat toxic epidermal necrolysis in a patient with a large skin injury: A case report.

Authors:  Dong-Dong Xue; Ling Zhou; Yong Yang; Si-Yuan Ma
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.